Medtronic to disclose doc payments

Medtronic announced that it will disclose payments to US physicians starting in 2011.

The Minneapolis-based device-maker said in February it would begin gathering information on consulting fees, royalties or honoraria next January and will report on payments to physicians receiving over $5,000 in March 2011 and annually, thereafter. Consulting agreements are understood to include counsel for areas such as education and training, clinical trial design and administration and product design and safety. Data will be posted to the company's website.

“Relationships between industry and doctors are essential to innovation, education and training in our industry,” said Medtronic chairman and CEO Bill Hawkins in a statement. “Through greater transparency about the nature of these relationships, we will help people better understand how important they are to developing life-saving and enhancing products for patients who need them.”

In August, Medtronic launched an online donations registry, reporting its donations to US customers or organizations affiliated with customers, including patient groups and medical societies.

A number of big pharmaceutical firms have rolled out similar transparency efforts in recent months, and Congress is likely to make reporting of payments to physicians of more than $100 mandatory under the Physician Payments Sunshine Act, currently pending in the Senate. Medtronic supports the legislation. 
“We will work hard with the bill sponsors to get this legislation passed,” said Hawkins. “These efforts will ensure a level playing field and consistency in reporting.”

Earlier in February, Pfizer announced plans to publicly disclose payments to US physicians, healthcare professionals and clinical investigators in excess of $500 per year, along with non-monetary items worth more than $25.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.